Covered in the latest feature of FirstWord Healthtech
Nicolas Stalder, senior investment associate at the fund, told FirstWord HealthTech that most of its current investments are Series A, which Debiopharm “will keep supporting as [the companies] progress through their path to scale.” Meanwhile, the fund will also back the most successful seed-stage start-ups through their subsequent Series A financing in its latest initiative.
Discover the full article here